...
首页> 外文期刊>Journal of Medicinal Chemistry >Exploring the structure-activity relationships of 1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand.
【24h】

Exploring the structure-activity relationships of 1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand.

机译:探索1-(4-叔丁基-3'-羟基)苯甲酰基-4-苄基哌嗪(SL-3111),一种高亲和力和选择性δ阿片受体非肽激动剂配体的构效关系。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

SL-3111 1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine is a de novo designed, high-affinity and selective nonpeptide peptidomimetic agonist of the delta-opioid receptor. In a previous report we had described the unique biological characteristics of this ligand and also a need for further structural evaluation.(6) To pursue this, we have introduced a completely different heterocyclic template (2 and 3), which, based on molecular modeling studies, may present the required structural features to properly orient the pharmacophore groups. We also have made more subtle changes to the original piperazine scaffold (5 and 11). The biological activities of these compounds revealed an important participation of the scaffold in the ligand-receptor interaction. To further explore functional diversity on the scaffold, we have maintained the original piperazine ring and introduced four different functionalities at position 2 of the heterocyclic ring (15a-d; a = CH(2)-O-CH(2)-Ph; b = Me; c = CH(2)Ph; d = CH(2)OH). The biological activities observed for these compounds showed a very interesting trend in terms of the steric effects of the groups introduced at this position. A decrease of almost 2000-fold in affinity and potency at the delta-receptor was observed for 15c compared with 15b. This difference may be explained if we postulate that the bioactive conformation of these peptidomimetics is close to the minimal energy conformations calculated in our study. On the basis of these findings we have realized the importance of this position to further explore and simplify the structure of future generations of peptidomimetic ligands.
机译:SL-3111 1-(4-叔丁基-3'-羟基)苯甲酰基-4-苄基哌嗪是从头设计的δ-阿片样物质受体的高亲和力和选择性非肽拟肽激动剂。在以前的报告中,我们描述了该配体的独特生物学特性,并且还需要进行进一步的结构评估。(6)为此,我们引入了完全不同的杂环模板(2和3),该模板基于分子建模研究表明,可能需要适当地定位药效团基团的结构特征。我们还对原始的哌嗪支架(5和11)进行了更细微的更改。这些化合物的生物学活性表明支架在配体-受体相互作用中的重要参与。为了进一步探索支架上的功能多样性,我们保持了原始哌嗪环并在杂环的位置2(15a-d; a = CH(2)-O-CH(2)-Ph; b = Me; c = CH(2)Ph; d = CH(2)OH)。就在该位置引入的基团的空间效应而言,观察到的这些化合物的生物活性显示出非常有趣的趋势。与15b相比,对于15c观察到在δ受体上亲和力和效力降低了近2000倍。如果我们假设这些拟肽的生物活性构象接近我们研究中计算的最小能量构象,则可以解释这种差异。在这些发现的基础上,我们已经意识到这一立场对进一步探索和简化后代拟肽配体的结构的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号